Vaccines Against Prostate Cancer:

Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential

Informed Prostate Cancer Support Group

March 2026  |  Special Feature: Cancer Immunotherapy

Feature Article · Immunotherapy

From Proven Therapy to the mRNA Frontier

A major new immunotherapy is heading toward FDA approval, mRNA cancer vaccines are entering pivotal trials, and a promising "tumor autovaccination" strategy has shown proof of concept — here is what the latest science means for men with prostate cancer.

Prepared for IPCSG Members  |  March 2026  |  Reviewed against published peer-reviewed literature and official regulatory releases

BLUF — Bottom Line Up Front

The idea of using the immune system itself to fight prostate cancer is no longer just a promise — it is increasingly a reality. One therapeutic vaccine, Provenge® (sipuleucel-T), has been FDA-approved for over a decade and continues to extend survival in men with metastatic castration-resistant prostate cancer. A second immunotherapy, CAN-2409 (aglatimagene besadenovec), completed a positive Phase 3 trial in December 2024, earned FDA Regenerative Medicine Advanced Therapy (RMAT) designation in May 2025, and its maker plans to submit a Biologics License Application by the end of 2026 — potentially bringing the first new localized prostate cancer therapy in more than 20 years. Meanwhile, personalized mRNA cancer vaccines are advancing rapidly through clinical trials, with prostate cancer included in multiple active programs. Early mRNA vaccine trials showed safety and immune activation but mixed clinical results; current research is focused on fixing those limitations through better antigen targeting, combination strategies with checkpoint inhibitors, and new delivery technologies. The bottom line: cancer vaccine science for prostate cancer is moving faster than at any point in history, even as each new therapy must still prove itself in rigorous trials.

1. What Is a Cancer Vaccine — and How Is It Different From a Preventive Vaccine?

Most of us learned about vaccines in the context of preventing infections — flu shots, COVID-19 vaccines, childhood immunizations. A therapeutic cancer vaccine works differently: rather than preventing a disease before it starts, it is given to a person who already has cancer, with the goal of training or amplifying the immune system to recognize and attack tumor cells.

The immune system has specialized cells — particularly cytotoxic T cells and CD4+ helper T cells — that can theoretically identify cancer cells as foreign and destroy them. The challenge in prostate cancer is that the immune environment inside and around the tumor is often suppressed or "quiet," making it hard for the immune system to mount a meaningful attack on its own. Vaccines aim to overcome that barrier.

There are also prophylactic (preventive) cancer vaccines — the best-known examples being the HPV vaccine, which prevents cervical and other cancers caused by human papillomavirus, and the Hepatitis B vaccine, which prevents liver cancer. To date, the FDA has approved no preventive vaccine for non-viral prostate cancer. All current prostate cancer vaccine work is focused on therapeutic approaches.

2. What We Already Have: Sipuleucel-T (Provenge®)

For men with mCRPC, the only FDA-approved therapeutic cancer vaccine is sipuleucel-T, marketed as Provenge®. It remains the first and only cancer vaccine ever approved by the FDA for any cancer type.

Sipuleucel-T works by removing white blood cells (specifically antigen-presenting cells) from the patient's own blood through a process called leukapheresis. These cells are then exposed outside the body to a fusion protein called PA2024, which combines a prostate cancer protein (PAP) with an immune activating signal (GM-CSF). After this "loading," the cells are infused back into the patient over three sessions roughly two weeks apart. The activated cells then help teach the immune system to recognize and attack prostate cancer.

📊 Sipuleucel-T: What the Pivotal Trial Showed

In the landmark IMPACT Phase 3 trial (published in the New England Journal of Medicine, 2010), 512 men with asymptomatic or minimally symptomatic mCRPC were randomized 2:1 to sipuleucel-T or placebo. Sipuleucel-T produced a 22% reduction in the risk of death, translating to a 4.1-month improvement in median overall survival (25.8 months vs. 21.7 months). The proportion alive at three years was 31.7% in the vaccine group vs. 23.0% in the placebo group. The most common side effects — chills, fatigue, and fever — were generally mild and resolved within 1–2 days.

Sipuleucel-T's benefit is real but modest, and there is a practical paradox: it often does not slow PSA progression or shrink tumors measurably, even as it extends life. This reflects the delayed and complex nature of immune responses. Researchers continue to study whether using it earlier in the disease course or combining it with other treatments — such as checkpoint inhibitors or hormone therapy — could improve outcomes.

3. The Next Therapy Approaching FDA Approval: CAN-2409

The most advanced vaccine-related therapy heading toward regulatory approval is CAN-2409 (also called aglatimagene besadenovec or ProstAtak), developed by Candel Therapeutics. While technically a gene therapy rather than a classic vaccine, it generates an immune response in a manner that functions very much like an in-situ (in-place) cancer vaccine, and it represents the most significant near-term development for men with localized prostate cancer.

CAN-2409 is an off-the-shelf, replication-defective adenovirus (a modified virus that cannot spread) that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells. When the patient then takes the oral prodrug valacyclovir, the HSV-tk enzyme converts it into a substance that kills cancer cells in an immunogenic (immune-activating) way — triggering the immune system to recognize the dying cancer cells and mount a broader attack. The process acts as a personalized cancer vaccine created from the patient's own tumor.

🏆 CAN-2409 Phase 3 Results (December 2024) and FDA Status (May 2025)

In a Phase 3 placebo-controlled trial of 745 men with newly diagnosed intermediate-to-high-risk localized prostate cancer receiving standard radiation therapy:

• 30% reduction in the risk of prostate cancer recurrence or death from any cause (HR 0.70; p=0.0155)
• 38% reduction in prostate cancer–specific recurrence or death (HR 0.62; p=0.0046)
• 80.4% pathological complete response rate at 2-year biopsy vs. 63.6% with placebo (p=0.0015)
• Significantly more patients achieved a PSA nadir below 0.2 ng/mL in the treatment arm
• No new safety signals; treatment-related adverse events were mild to moderate and self-limited

In May 2025, the FDA granted CAN-2409 Regenerative Medicine Advanced Therapy (RMAT) Designation — its second expedited designation after an earlier Fast Track designation. A Biologics License Application (BLA) is expected to be submitted to the FDA by the end of 2026.

If approved, CAN-2409 would be the first genuinely new therapy for localized prostate cancer in more than 20 years — a significant milestone. The RMAT designation enables intensive FDA guidance and the potential for accelerated review. Candel Therapeutics has stated its goal is to provide a new option for men with early-stage prostate cancer who seek curative treatment with minimal innovation having occurred over two decades in that space.

4. mRNA Cancer Vaccines: From COVID Success to Cancer Trials

The rapid global success of Pfizer-BioNTech and Moderna's mRNA COVID-19 vaccines dramatically accelerated interest in applying the same technology to cancer. The principle is similar but the target is different: instead of teaching the immune system to recognize a virus, an mRNA cancer vaccine teaches it to recognize proteins found on cancer cells — proteins called neoantigens (mutations unique to a patient's tumor) or tumor-associated antigens (proteins more broadly overexpressed in cancer).

mRNA vaccines are particularly attractive for cancer because they can be designed and manufactured rapidly, they do not integrate into the patient's DNA, and they can be personalized. After a tumor is biopsied or removed, its DNA is sequenced and compared to normal cells. The unique mutations driving that cancer are identified, and mRNA encoding those mutations is synthesized and packaged into lipid nanoparticles (LNPs). The resulting custom vaccine is specific to that individual's cancer.

Advances in artificial intelligence-driven neoantigen selection have accelerated this process. The time required to identify the best neoantigens from a patient's tumor has been compressed from weeks to hours in some systems. Manufacturing timelines are also shortening, with hybrid approaches combining common shared antigen components with patient-specific sequences potentially enabling vaccine production in under four weeks — compared to six to nine weeks previously.

"Cancer vaccines were once seen as a promising idea that struggled to deliver durable clinical benefit. Today, advances in sequencing, immune profiling, and vaccine platforms are transforming that landscape."

— Dr. Nina Bhardwaj, Director, Vaccine and Cell Therapy Laboratory, Icahn School of Medicine at Mount Sinai (January 2026)

5. mRNA Vaccine History in Prostate Cancer: The Lessons Learned

Prostate cancer has been part of mRNA vaccine research for more than a decade. The first notable effort was CV9103 and its successor CV9104, developed by CureVac using the RNActive® platform (later acquired/associated with BioNTech). CV9104 was an mRNA-based vaccine encoding six prostate cancer–associated antigens: PSA, PSMA, PSCA, STEAP1, PAP, and MUC1.

In a randomized Phase I/IIb trial reported at ESMO 2017, CV9104 was tested in 197 men with metastatic castration-resistant prostate cancer. The results were instructive in both directions: 64% of patients developed measurable immune (T-cell) responses to the vaccine antigens — a genuine biological success. However, the trial found no significant improvement in overall survival: median OS was 35.5 months in the vaccine arm vs. 33.7 months in the placebo arm. There were no new safety concerns.

Researchers concluded that while the vaccine could activate the immune system, it was not enough on its own against the immunosuppressive environment of advanced prostate cancer. These lessons — that immune activation alone doesn't necessarily translate to clinical benefit — have driven the current generation of research to focus on combinations, earlier-stage use, and next-generation delivery platforms.

6. The Current Frontier: New mRNA Approaches in Prostate Cancer

Personalized Neoantigen Vaccines (PGV001)

Mount Sinai researchers led by Dr. Nina Bhardwaj published Phase 1 results in March 2025 of PGV001, a personalized multi-peptide neoantigen cancer vaccine. In this early-stage study of 13 patients across multiple cancer types, the vaccine was safe, well tolerated, and at five-year follow-up, 3 of the 6 surviving patients were tumor-free. Importantly, the data prompted a new trial specifically for prostate cancer patients. The vaccine works by sequencing each patient's tumor, using a computational platform to select the most immunogenic neoantigens, and formulating a personalized peptide vaccine targeting those specific mutations.

Intratumoral "Autovaccination" Strategy (Mount Sinai / Icahn School of Medicine)

In October 2025, a Phase 1 trial published in the journal Med (Cell Press) by Dr. Ash Tewari and colleagues at Mount Sinai reported a novel approach for men with intermediate-to-high-risk prostate cancer prior to surgery. The strategy involved injecting an immune-activating compound called poly-ICLC (a viral-mimicking drug) directly into the prostate tumor under MRI-ultrasound fusion guidance, followed by a muscle injection to boost the response. This turned the tumor into its own vaccine — a strategy called "autovaccination."

In 12 patients, the approach was safe and successfully "reawakened" local immune responses in the tumor, with evidence of immune cell activation in tissue and blood samples. This is believed to be the first prostate cancer trial testing direct intratumoral immunotherapy. The research team is advancing to larger Phase 2 controlled trials, and the approach could eventually be combined with hormone therapies or checkpoint inhibitors.

Moderna's mRNA-4157 (V940) Platform — Prostate Cancer in the Pipeline

Moderna's personalized mRNA cancer vaccine, mRNA-4157 (V940), in combination with Merck's checkpoint inhibitor pembrolizumab (Keytruda®), has generated extraordinary results in melanoma — reducing recurrence risk by 44% and distant metastasis risk by 65% compared to pembrolizumab alone in a Phase 2b trial. A Phase 3 trial (INTerpath-009) is underway.

Based on that success, additional candidates in prostate cancer are preparing for late-stage clinical development, with regulatory submissions anticipated in the 2026–2029 timeframe. AI-driven neoantigen prediction, improvements in lipid nanoparticle delivery, and faster manufacturing are all enabling this expansion into prostate cancer and other tumor types.

📋 Selected Active/Recent Vaccine Programs with Prostate Cancer Relevance

Vaccine / Agent	Type	Status	Key Results / Note
Sipuleucel-T (Provenge®)	Dendritic cell (autologous)	FDA-Approved (2010)	4.1-month OS benefit in mCRPC; only approved cancer therapeutic vaccine
CAN-2409 (aglatimagene besadenovec)	Gene therapy / in-situ vaccine	Phase 3 complete; BLA filing anticipated late 2026; RMAT designated	30% reduction in recurrence/death in localized PCa + radiation; 80.4% pathological CR at 2 years
CV9104 (CureVac/BioNTech)	mRNA (6 antigens)	Phase IIb complete (negative)	64% immune activation; no OS improvement in mCRPC — taught key lessons
PGV001 (Mount Sinai)	Personalized neoantigen peptide vaccine	Phase 1 complete; prostate cancer trial initiated	Safe; 3/6 survivors tumor-free at 5 years across multiple cancers
Poly-ICLC intratumoral (Mount Sinai)	Immune agonist / autovaccination	Phase 1 complete; Phase 2 planned	First intratumoral approach in PCa; proof of concept for immune reawakening
mRNA-4157 / V940 (Moderna + Merck)	Personalized mRNA neoantigen	Phase 3 (melanoma/NSCLC); PCa candidates in pipeline	44% recurrence reduction in melanoma; PCa submissions anticipated 2026–2029
pTVG-AR DNA vaccine (McNeel lab)	DNA vaccine (androgen receptor LBD)	Phase 1 complete	Well tolerated in mCSPC; patients with T-cell immunity had significantly extended PFS (HR=0.01)

7. Why Is Prostate Cancer Hard to Vaccinate Against?

Prostate cancer presents specific challenges for cancer vaccines that researchers are actively working to overcome:

Low neoantigen burden: Unlike melanoma, which has thousands of mutations that can serve as vaccine targets, prostate cancer tends to accumulate fewer mutations. This means there are fewer unique "flags" to identify as cancer-specific — a smaller target list for personalized vaccines. Researchers are working on multi-antigen approaches and on targeting driver mutations shared among many patients.

Immunosuppressive tumor microenvironment: Prostate tumors actively suppress immune activity in and around the tumor. They recruit regulatory immune cells and produce signals that "quiet" T cells, making it harder for even a well-primed immune response to penetrate and kill cancer cells. Combining vaccines with checkpoint inhibitors (drugs that release these immune brakes) is a major area of current research.

Immune tolerance to prostate-specific proteins: Because PSA and prostatic acid phosphatase (PAP) are normal prostate proteins, the immune system may treat them as "self" and be reluctant to attack them vigorously — a phenomenon called central tolerance. Vaccines encoding these antigens must overcome this barrier.

Timing matters: Emerging data consistently show that vaccines work better earlier in the disease course, when the immune system is less exhausted and tumor burden is lower. Most early trials enrolled men with advanced or heavily pretreated disease — conditions that are hardest for any immunotherapy. Trials are increasingly being designed for earlier stages.

8. The Combination Strategy: Why Vaccines Are Unlikely to Work Alone

One of the most important insights from a decade of prostate cancer vaccine research is that vaccines are most likely to succeed as part of combination regimens. Leading combinations under investigation include:

Vaccines + Checkpoint Inhibitors (anti-PD-1/PD-L1): Checkpoint inhibitors release immune brakes that tumors exploit. When combined with a vaccine that "primes" the immune system to recognize cancer, the two approaches can create a synergistic effect — the vaccine generates tumor-specific T cells, and the checkpoint inhibitor keeps those T cells from being suppressed. BioNTech is currently combining its CV9104-successor approaches with avelumab in prostate cancer trials.

Vaccines + Androgen Deprivation Therapy (ADT): ADT has been shown to increase the infiltration of immune cells (tumor-infiltrating lymphocytes) into prostate tumors, potentially making tumors more susceptible to vaccine-generated immune attacks. Several trials are exploring this sequencing.

Vaccines + Radiation: CAN-2409's success comes precisely from combining immunogenic tumor cell death (caused by the gene therapy) with radiation — creating a "one-two punch" that both kills cancer cells and amplifies the immune response. Similarly, radiofrequency ablation and other local treatments are being studied as immune-sensitizing strategies before vaccination.

9. Addressing a Concern: The "Turbo Cancer" Misinformation

⚠️ Important: Separating Fact from Misinformation

You may have encountered social media claims that COVID-19 mRNA vaccines cause a phenomenon called "turbo cancer" — the idea that they make existing cancers grow more aggressively. This claim is not supported by credible scientific evidence. Large population studies have found no increased cancer risk following COVID-19 vaccination. In September 2025, a U.K. cardiologist made public claims linking COVID-19 vaccines to the British royal family's cancer diagnoses; this was immediately rebutted by the wider medical community as an unsupported claim.

Researchers in health communication who monitor online conversations documented widespread "turbo cancer" misinformation beginning in 2023 and continuing through early 2026, driven by emotional anecdotes and misrepresented animal studies. The concern that this narrative raises for our community is real: false claims about mRNA safety could cause men to refuse genuinely promising mRNA cancer vaccine therapies in the future — therapies that use the same underlying technology but are specifically designed to fight cancer, not prevent a viral infection. If you encounter these claims, please discuss them with your oncologist.

10. What This Means for IPCSG Members: Questions to Ask Your Doctor

Here are some practical points and questions that may be relevant to your situation, depending on your disease stage:

If you have asymptomatic or minimally symptomatic mCRPC: Ask your oncologist whether sipuleucel-T (Provenge®) is appropriate for your situation. It remains an FDA-approved option. It is often most effective when immune function is preserved, and it does not preclude other treatments.

If you have newly diagnosed intermediate-to-high-risk localized prostate cancer being treated with radiation: Ask about CAN-2409 clinical trial participation or, as the FDA application moves forward, availability upon approval — expected no sooner than 2027 given the BLA submission timeline of late 2026.

If you are interested in vaccine clinical trials: Personalized neoantigen vaccine trials and intratumoral immunotherapy approaches are actively enrolling. Ask your oncologist about eligibility for trials listed on ClinicalTrials.gov. UCSD, Mount Sinai, and other major academic centers are among the sites conducting prostate cancer vaccine research.

On cost and access: Personalized mRNA vaccines currently cost an estimated $100,000–$300,000 per patient to produce. This is a significant access challenge. As manufacturing scales and regulatory approvals arrive, reimbursement frameworks will be critical. Stay informed and advocate with your insurance and legislators.

🔬 The State of the Science: A Realistic Assessment

Cancer vaccines for prostate cancer are at a genuine inflection point. We have one proven, approved option (Provenge®). We have one highly promising therapy with a positive Phase 3 trial heading toward FDA review (CAN-2409). We have an mRNA vaccine technology platform that has now produced major results in melanoma and is being studied in prostate cancer. And we have a new generation of personalized, AI-guided neoantigen vaccines entering prostate-specific trials. None of this means every man with prostate cancer will have a vaccine option tomorrow. But for the first time in the history of this disease, the scientific momentum behind immune-based therapy for prostate cancer is unmistakably moving forward on multiple fronts simultaneously.

Verified Sources & Formal Citations

1. Kantoff PW, Higano CS, Shore ND, et al. "Sipuleucel-T immunotherapy for castration-resistant prostate cancer." New England Journal of Medicine. 2010;363(5):411–422.
   https://www.nejm.org/doi/full/10.1056/NEJMoa1001294
2. Cheever MA, Higano CS. "PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine." Clinical Cancer Research. 2011;17(11):3520–3526.
   https://aacrjournals.org/clincancerres/article/17/11/3520/12151/
3. Candel Therapeutics. "Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer." News release. May 28, 2025.
   https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced
4. Candel Therapeutics. "Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival." News release. December 11, 2024.
   https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint
5. Gejerman G, et al. "Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer." Presented at: ASTRO 2025 Annual Meeting; September 28–30, 2025; San Francisco, CA. Reported by UroToday.
   https://www.urotoday.com/conference-highlights/astro-2025/
6. Tewari AK, et al. "Intratumoral poly-ICLC immunotherapy before radical prostatectomy in intermediate-to-high-risk prostate cancer." Med (Cell Press). October 30, 2025. DOI: 10.1016/j.medj.2025.100879.
   Reported at: https://www.mountsinai.org/about/newsroom/2025/early-clinical-trial-tests-immune-boosting-therapy
7. Mount Sinai. "Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai." News release. March 17, 2025. (PGV001 trial.)
   https://www.mountsinai.org/about/newsroom/2025/personalized-cancer-vaccine-proves-promising-in-a-phase-1-trial-at-mount-sinai
8. Mount Sinai. "Mount Sinai Review Maps the Path Forward for Cancer Vaccines, Highlighting Promise of Personalized and Combination Approaches." News release. January 22, 2026. (Bhardwaj et al., Cell Reports Medicine.)
   https://www.mountsinai.org/about/newsroom/2026/mount-sinai-review-maps-the-path-forward-for-cancer-vaccines
9. Stenzl A, Feyerabend S, Syndikus I, et al. "Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)." Annals of Oncology. 2017;28(suppl 5):v408–v409.
   https://www.annalsofoncology.org/article/S0923-7534(20)38416-7/fulltext
10. Xu Z, Shi Y, et al. "Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next." npj Vaccines. January 7, 2026.
    https://www.nature.com/articles/s41541-025-01358-9
11. Mirabile-Brightman SE, Butterfield LH. "Advances in the development of personalized neoantigen therapies." Journal of Experimental Medicine. 2026;223(2):e20241234. DOI: 10.1084/jem.20241234.
    https://rupress.org/jem/article/223/2/e20241234/278560/
12. Luo H, et al. "Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update." PMC/NLM. 2025.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12153701/
13. Yang J, et al. "mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics." Cancer Innovation. December 8, 2025. DOI: 10.1002/cai2.70041.
    https://onlinelibrary.wiley.com/doi/full/10.1002/cai2.70041
14. Peng H, et al. "Advances in Neoantigen-Based Cancer Vaccines." PMC/NLM. January 2026.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12784945/
15. Wang C, et al. "Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook." PMC/NLM. 2024.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC11679746/
16. Boatman DD. "Cancer vaccines could transform treatment and prevention — but misinformation about mRNA vaccines threatens their potential." The Conversation. 2025–2026.
    https://theconversation.com/cancer-vaccines-could-transform-treatment-and-prevention
17. de Bono JS, et al. "Vaccines as treatments for prostate cancer." Nature Reviews Urology. March 6, 2023.
    https://www.nature.com/articles/s41585-023-00739-w
18. PROVENGE® (sipuleucel-T). Official prescribing information and patient site.
    https://provenge.com/
19. ClinicalTrials.gov. Phase 3 study of ProstAtak immunotherapy with standard radiation therapy for localized prostate cancer (PrTK03). NCT01436968.
    https://clinicaltrials.gov/study/NCT01436968
20. ASCO Post. "New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024, and November 19, 2025." December 10, 2025.
    https://ascopost.com/issues/december-10-2025/new-fda-approved-oncology-drugs-and-label-updates/

Informed Prostate Cancer Support Group (IPCSG)
This newsletter article is prepared for educational purposes and is not a substitute for personalized medical advice. Always consult your oncologist or urologist before making treatment decisions.
© 2026 IPCSG  |  San Diego, California